DNAJB5

Summary

DNAJB5 (DnaJ heat shock protein family (Hsp40) member B5, HGNC:14887) is a protein-coding gene on chromosome 9p13.3, encoding DnaJ homolog subfamily B member 5 (O75953).

This gene encodes a member of the DNAJ heat shock protein 40 family of co-chaperone proteins. The encoded protein contains an N-terminal DNAJ domain and a C-terminal substrate binding domain but lacks the cysteine-rich domain found in other DNAJ family members. In mice, a multi-protein complex containing this protein, thioredoxin 1, and histone deacetylase 4, serves as a master negative regulator of cardiac hypertrophy.

Source: NCBI Gene 25822 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 63 total
• MANE Select transcript: NM_001349723

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14887
Approved symbol	DNAJB5
Name	DnaJ heat shock protein family (Hsp40) member B5
Location	9p13.3
Locus type	gene with protein product
Status	Approved
Aliases	Hsc40
Ensembl gene	ENSG00000137094
Ensembl biotype	protein_coding
OMIM	611328
Entrez	25822

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 10 protein_coding, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000312316, ENST00000443266, ENST00000453597, ENST00000454002, ENST00000458263, ENST00000469798, ENST00000537321, ENST00000539059, ENST00000541010, ENST00000545841, ENST00000682809, ENST00000684748

RefSeq mRNA: 6 — MANE Select: NM_001349723 NM_001135004, NM_001135005, NM_001349723, NM_001349724, NM_001349725, NM_012266

CCDS: CCDS35007, CCDS47959, CCDS47960

Canonical transcript exons

ENST00000682809 — 5 exons

Exon	Start	End
ENSE00001817118	34989745	34989831
ENSE00003555966	34993200	34993444
ENSE00003694741	34996265	34996866
ENSE00003916996	34990499	34990812
ENSE00003918669	34997026	34998428

Expression profiles

Bgee: expression breadth ubiquitous, 241 present calls, max score 97.65.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 17.3179 / max 405.7396, expressed in 1753 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
96552	14.5656	1748
96557	1.1082	131
96553	0.9522	287
96555	0.2607	82
96554	0.2505	110
96556	0.1164	31
205469	0.0642	22

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
hindlimb stylopod muscle	UBERON:0004252	97.65	gold quality
saphenous vein	UBERON:0007318	96.69	gold quality
gastrocnemius	UBERON:0001388	96.64	gold quality
cortical plate	UBERON:0005343	96.37	gold quality
muscle of leg	UBERON:0001383	95.86	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.51	gold quality
ganglionic eminence	UBERON:0004023	95.50	gold quality
lower esophagus	UBERON:0013473	95.47	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	94.96	gold quality
apex of heart	UBERON:0002098	94.80	gold quality
muscle organ	UBERON:0001630	94.64	gold quality
skeletal muscle organ	UBERON:0014892	94.64	gold quality
mucosa of stomach	UBERON:0001199	94.25	gold quality
tibial artery	UBERON:0007610	94.05	gold quality
popliteal artery	UBERON:0002250	94.03	gold quality
vena cava	UBERON:0004087	93.85	gold quality
aorta	UBERON:0000947	93.36	gold quality
heart left ventricle	UBERON:0002084	93.02	gold quality
cardiac ventricle	UBERON:0002082	92.96	gold quality
body of tongue	UBERON:0011876	92.88	gold quality
muscle layer of sigmoid colon	UBERON:0035805	92.83	gold quality
triceps brachii	UBERON:0001509	92.57	gold quality
ascending aorta	UBERON:0001496	92.52	gold quality
thoracic aorta	UBERON:0001515	92.50	gold quality
right atrium auricular region	UBERON:0006631	92.32	gold quality
left uterine tube	UBERON:0001303	92.28	gold quality
skeletal muscle tissue	UBERON:0001134	92.14	gold quality
biceps brachii	UBERON:0001507	91.91	gold quality
heart	UBERON:0000948	91.75	gold quality
cardiac atrium	UBERON:0002081	91.57	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.59

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

160 targeting DNAJB5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4715-3P	99.98	66.03	670
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-381-3P	99.93	71.87	2854

Literature-anchored findings (GeneRIF, showing 1)

• Critical role of zebrafish dnajb5 in myocardial proliferation and regeneration. (PMID:33191150)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	dnajb5	ENSDARG00000052881
mus_musculus	Dnajb5	ENSMUSG00000036052
rattus_norvegicus	Dnajb5	ENSRNOG00000000130
drosophila_melanogaster	CG2887	FBGN0030207
drosophila_melanogaster	CG5001	FBGN0031322
drosophila_melanogaster	CG30156	FBGN0050156
drosophila_melanogaster	DnaJ-1	FBGN0263106

Paralogs (11): DNAJB11 (ENSG00000090520), DNAJB6 (ENSG00000105993), DNAJB9 (ENSG00000128590), DNAJB1 (ENSG00000132002), DNAJB2 (ENSG00000135924), DNAJB12 (ENSG00000148719), DNAJB4 (ENSG00000162616), DNAJB14 (ENSG00000164031), DNAJB7 (ENSG00000172404), DNAJB8 (ENSG00000179407), DNAJB13 (ENSG00000187726)

Protein

Protein identifiers

DnaJ homolog subfamily B member 5 — O75953 (reviewed: O75953)

Alternative names: Heat shock protein Hsp40-2, Heat shock protein Hsp40-3, Heat shock protein cognate 40

All UniProt accessions (7): A0A7I2RN43, O75953, H0Y4S1, H0YFL9, H0YH04, H7C5W0, Q5T657

UniProt curated annotations — full annotation on UniProt →

Induction. Expressed under normal conditions, its expression can further be increased after various stress treatments.

Isoforms (3)

UniProt ID	Names	Canonical?
O75953-3	1	yes
O75953-4	2
O75953-5	3

RefSeq proteins (6): NP_001128476, NP_001128477, NP_001336652, NP_001336653, NP_001336654, NP_036398 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001623	DnaJ_domain	Domain
IPR002939	DnaJ_C	Domain
IPR008971	HSP40/DnaJ_pept-bd	Homologous_superfamily
IPR018253	DnaJ_domain_CS	Conserved_site
IPR036869	J_dom_sf	Homologous_superfamily
IPR051339	DnaJ_subfamily_B	Family

Pfam: PF00226, PF01556

UniProt features (6 total): splice variant 2, sequence conflict 2, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75953-F1	80.69	0.48

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 231 (showing top): RNGTGGGC_UNKNOWN, PAX4_01, SP3_Q3, CAGCTG_AP4_Q5, NFKB_Q6, SHAFFER_IRF4_TARGETS_IN_PLASMA_CELL_VS_MATURE_B_LYMPHOCYTE, CHEN_LVAD_SUPPORT_OF_FAILING_HEART_UP, GOBP_PROTEIN_MATURATION, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, MYCMAX_01, GGARNTKYCCA_UNKNOWN, chr9p13, TGIF_01, TCCCCAC_MIR491, ZIC1_01

GO Biological Process (3): negative regulation of transcription by RNA polymerase II (GO:0000122), protein folding (GO:0006457), response to unfolded protein (GO:0006986)

GO Molecular Function (3): obsolete unfolded protein binding (GO:0051082), protein-folding chaperone binding (GO:0051087), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), cytosol (GO:0005829), endoplasmic reticulum lumen (GO:0005788)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
cellular process	1
protein maturation	1
response to topologically incorrect protein	1
protein binding	1
binding	1
intracellular membrane-bounded organelle	1
cytoplasm	1
cellular anatomical structure	1
endoplasmic reticulum	1
intracellular organelle lumen	1

Protein interactions and networks

STRING

2329 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DNAJB5	HSPA8	P11142	696
DNAJB5	HSPA4	P34932	563
DNAJB5	TXN	P10599	539
DNAJB5	HDAC4	P56524	490
DNAJB5	ISOC1	Q96CN7	472
DNAJB5	DNAJB6	O75190	444
DNAJB5	GOLPH3L	Q9H4A5	437
DNAJB5	TXN2	Q99757	419
DNAJB5	VGLL4	Q14135	418
DNAJB5	PIK3C2B	O00750	400
DNAJB5	SMURF2	Q9HAU4	395
DNAJB5	STXBP1	P61764	394
DNAJB5	GNA13	Q14344	385
DNAJB5	ARRDC4	Q8NCT1	383
DNAJB5	ING3	Q9NXR8	377
DNAJB5	ARRDC1	Q8N5I2	377

IntAct

104 interactions, top by confidence:

A	B	Type	Score
MLF1	DNAJB6	psi-mi:“MI:0914”(association)	0.750
DNAJB4	DNAJB5	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
TRIM16L	CCDC22	psi-mi:“MI:0914”(association)	0.640
DNAJB1	DNAJB5	psi-mi:“MI:0914”(association)	0.640
EBNA-LP	DNAJB5	psi-mi:“MI:0915”(physical association)	0.620
EBNA-LP	HAX1	psi-mi:“MI:0914”(association)	0.530
MANSC1	KLRG2	psi-mi:“MI:0914”(association)	0.530
NPAS1	DNAJB5	psi-mi:“MI:0914”(association)	0.530
TFDP3	E2F3	psi-mi:“MI:0914”(association)	0.530
DNAJB4	SYNM	psi-mi:“MI:0914”(association)	0.530
BAG4	DNAJC13	psi-mi:“MI:0914”(association)	0.530
P2RX6	DNAJB5	psi-mi:“MI:0914”(association)	0.530
TKTL1	DNAJB5	psi-mi:“MI:0914”(association)	0.530
ASB4	DNAJB5	psi-mi:“MI:0914”(association)	0.530
FBXW11	AHCYL1	psi-mi:“MI:0914”(association)	0.530
KCNE3	RIOK3	psi-mi:“MI:0914”(association)	0.530
CACNA1A	DNAJB5	psi-mi:“MI:0915”(physical association)	0.510

BioGRID (157): DNAJB5 (Affinity Capture-Western), DNAJB5 (Affinity Capture-Western), DNAJB5 (Affinity Capture-MS), DNAJB5 (Affinity Capture-MS), DNAJB5 (Affinity Capture-MS), DNAJB5 (Affinity Capture-MS), DNAJB5 (Affinity Capture-MS), DNAJB5 (Affinity Capture-MS), DNAJB5 (Affinity Capture-MS), DNAJB5 (Co-fractionation), HYOU1 (Co-fractionation), DNAJB5 (Affinity Capture-MS), DNAJB5 (Affinity Capture-MS), DNAJB5 (Affinity Capture-MS), DNAJB5 (Affinity Capture-MS)

ESM2 similar proteins: A6QBG7, B9FHF3, O35824, O60884, O74752, O75953, O89114, O94625, O94657, P25294, P25303, P25491, P25685, P42824, P42825, P43644, P59910, P78004, P81999, Q03363, Q04960, Q09912, Q0JB88, Q24133, Q2HJ94, Q2KIT4, Q3AQP5, Q3MI00, Q3ZBA6, Q54ED3, Q5BIP8, Q5R8J8, Q5RAJ6, Q626I7, Q6MNG0, Q6TUG0, Q8A8C3, Q8GWW8, Q8MPX3, Q8TA83

Diamond homologs: A0A0P0VG31, A0LJ41, A1BHL1, A3QGW1, A4IR30, A6ZQH0, A7GT07, A7TGR0, A8F0U0, A8GMF8, A8GR21, A9IGC5, A9KE65, A9NDK6, A9VHU0, B0BWH0, B0UWR3, B1HUD0, B1YKT0, B2RLJ0, B7HCT9, B7HPL2, B7IYG6, B7JN38, B8CXL0, B8FUN3, B9DNJ9, B9E6X0, B9IY80, C1ESK7, C3L5R6, C3P8L9, C3PMM6, C4K111, C5D4U0, O52065, O75953, O89114, P0CW06, P0CW07

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 111 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of HSF1-mediated heat shock response	6	13.1×	2e-03
RHOA GTPase cycle	6	7.0×	8e-03

GO biological processes:

GO term	Partners	Fold	FDR
response to unfolded protein	5	16.2×	7e-03
protein folding	7	7.8×	7e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

63 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	52
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

904 predictions. Top by Δscore:

Variant	Effect	Δscore
9:34993393:GTGC:G	donor_gain	1.0000
9:34993394:TGCT:T	donor_gain	1.0000
9:34993395:GC:G	donor_gain	1.0000
9:34993396:C:G	donor_gain	1.0000
9:34993440:GGAAG:G	donor_gain	1.0000
9:34993441:GAAGG:G	donor_gain	1.0000
9:34993442:A:T	donor_gain	1.0000
9:34993445:G:GA	donor_loss	1.0000
9:34993446:T:G	donor_loss	1.0000
9:34996260:TCTA:T	acceptor_loss	1.0000
9:34996261:CTA:C	acceptor_loss	1.0000
9:34996263:A:AG	acceptor_gain	1.0000
9:34996264:G:GG	acceptor_gain	1.0000
9:34996864:G:GT	donor_gain	1.0000
9:34996864:G:T	donor_gain	1.0000
9:34989829:CCGG:C	donor_loss	0.9900
9:34989831:GGTG:G	donor_loss	0.9900
9:34989832:G:GG	donor_gain	0.9900
9:34989832:GTG:G	donor_loss	0.9900
9:34989833:T:A	donor_loss	0.9900
9:34993194:TTTCA:T	acceptor_loss	0.9900
9:34993195:TTCA:T	acceptor_loss	0.9900
9:34993196:TCAG:T	acceptor_loss	0.9900
9:34993197:CA:C	acceptor_loss	0.9900
9:34993198:A:AG	acceptor_gain	0.9900
9:34993198:A:G	acceptor_loss	0.9900
9:34993199:G:GC	acceptor_gain	0.9900
9:34993199:GA:G	acceptor_gain	0.9900
9:34993199:GAA:G	acceptor_gain	0.9900
9:34993199:GAAAC:G	acceptor_gain	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000233810 (9:34987805 ACTC>A), RS1000289376 (9:34997714 A>G), RS1000403034 (9:34992708 C>T), RS1000835903 (9:34989195 T>C), RS1000934175 (9:34994377 C>A), RS1001738955 (9:34999116 G>A), RS1001776093 (9:34989295 C>T), RS1001828381 (9:34989519 C>A,T), RS1002196085 (9:34998798 G>A,C,T), RS1002572187 (9:34987885 C>A), RS1002735088 (9:34999322 T>C), RS1003089331 (9:34999208 C>A), RS1003457510 (9:34992709 G>A), RS1003511299 (9:34992995 G>A), RS1003796314 (9:34991213 C>G)

Disease associations

OMIM: gene MIM:611328 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): peripheral neuropathy (MONDO:0005244), skeletal muscle disorder (MONDO:0020120)

Orphanet (1): Skeletal muscle disease (Orphanet:98472)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST006295_12	Response to quetiapine in schizophrenia	6.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
potassium chromate(VI)	decreases expression, affects cotreatment	2
Methotrexate	decreases expression, increases expression	2
Tretinoin	increases expression, decreases expression	2
Particulate Matter	decreases expression, increases abundance, increases expression	2
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, increases expression	1
methylselenic acid	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	increases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
15-acetyldeoxynivalenol	increases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
nutlin 3	affects cotreatment, increases expression	1
abrine	increases expression	1
Sunitinib	decreases expression	1
Acetaminophen	increases expression	1
Air Pollutants	increases abundance, decreases expression	1
Vehicle Emissions	increases expression	1
Cisplatin	increases expression	1
Cycloheximide	decreases expression, decreases reaction	1
Dactinomycin	affects cotreatment, increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Estradiol	increases expression, affects cotreatment	1
Ethyl Methanesulfonate	increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Phenobarbital	affects expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00380965	PHASE4	COMPLETED	Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy
NCT00487981	PHASE4	TERMINATED	Spinal Cord Stimulation for Painful Diabetic Neuropathy
NCT00904202	PHASE4	COMPLETED	A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions
NCT01192113	PHASE4	COMPLETED	Safety and Efficacy of Mecobalamin Injection in Peripheral Neuropathies Patients (Study JGAZSY091109)
NCT01373983	PHASE4	COMPLETED	Intrathecal Bolus Doses of Ziconotide
NCT01458015	PHASE4	TERMINATED	Tapentadol Versus Oxycodone - a Mechanism-based Treatment Approach in Neuropathic Pain
NCT02074267	PHASE4	COMPLETED	Clinical Study for Assessment of the Efficacy of Gabapentin (Carbatin and Neurontin) in Patients With Neuropathy Pain
NCT02372149	PHASE4	UNKNOWN	IVIg for Demyelination in Diabetes Mellitus
NCT02670161	PHASE4	ENROLLING_BY_INVITATION	Quality Improvement and Practice Based Research in Neurology Using the EMR
NCT07022938	PHASE4	COMPLETED	Nutritional Supplement for Treating Chemotherapy Induced Neuropathy
NCT07025005	PHASE4	RECRUITING	Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)
NCT00058071	PHASE3	COMPLETED	Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer
NCT00125268	PHASE3	TERMINATED	Near Infrared Light for the Treatment of Painful Peripheral Neuropathy
NCT00195013	PHASE3	COMPLETED	Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy
NCT00232141	PHASE3	COMPLETED	Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy
NCT00264875	PHASE3	COMPLETED	Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy
NCT00369564	PHASE3	COMPLETED	Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
NCT00471445	PHASE3	COMPLETED	Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
NCT00489411	PHASE3	COMPLETED	Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
NCT00710554	PHASE3	COMPLETED	A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia
NCT00711880	PHASE3	COMPLETED	A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.
NCT00713323	PHASE3	COMPLETED	A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.
NCT00713817	PHASE3	COMPLETED	A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain
NCT00775645	PHASE3	COMPLETED	S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo
NCT00872352	PHASE3	UNKNOWN	Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients
NCT00998738	PHASE3	TERMINATED	Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
NCT01049217	PHASE3	TERMINATED	Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy
NCT01099449	PHASE3	COMPLETED	Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
NCT01288937	PHASE3	TERMINATED	A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain
NCT01492920	PHASE3	WITHDRAWN	Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
NCT01775449	PHASE3	COMPLETED	Prevention of Oxaliplatin-induced Neuropathic Pain by a Specific Diet
NCT02024191	PHASE3	UNKNOWN	The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy
NCT02217267	PHASE3	COMPLETED	Long Term Outcome After Serial Lidocaine Infusion in Peripheral Neuropathic Pain
NCT02294149	PHASE3	UNKNOWN	Vit D3 and Omega 3 in Chemo Induced Neuropathy
NCT02311907	PHASE3	COMPLETED	Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
NCT06071936	PHASE3	UNKNOWN	Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
NCT06071975	PHASE3	UNKNOWN	Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
NCT06071988	PHASE3	UNKNOWN	Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
NCT06072573	PHASE3	UNKNOWN	Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
NCT07287592	PHASE3	NOT_YET_RECRUITING	Glutamine for the Prophylaxis of Vincristine-induced Neuropathy in Children and Adolescents With Cancer.